Ulf Persson　ウルフ・パーソン

Senior advisor at the Swedish Institute for Health Economics (IHE). IHE was established in 1979 as the first centre for health economic research in Sweden.has a staff of about 30 health economists. Ulf was until end of 2017 the CEO at IHE and hold a position as adjunct professor in Health Economics at Lund University. He has also experiences as former director in health economics at Johnson & Johnson at NJ, in the US. He has almost 40 years research experience in the development and application of economic evaluation methods in health care. His main research areas are health economics, pharmaceutical economics, economic evaluations, and transport economics. He has published more than 300 articles, books and reports in health economics and economics of transport safety. He has 10 years experiences from price and reimbursement decisions both as a former member of the Swedish Dental Benefit Board and the Swedish Pharmaceutical Pricing and
Reimbursement Board, both included in the Dental and Pharmaceutical Benefits Agency (TLV).

スウェーデン医療経済研究所（IHE）シニアアドバイザー。IHEはスウェーデン初の医療経済研究センターとして1979年に設立され、約30名の医療経済学者が在籍している。2017年末まで、IHE CEO、ルンド大学 医療経済学 非常勤教授を兼任。米国ジョンソン・エンド・ジョンソン社（ニュージャージー州）にて医療経済学の元ディレクター、ヘルスケアにおける経済評価手法の開発・応用において、約40年の研究経験を持つ。主な研究分野は、医療経済学、薬剤経済学、経済評価、交通経済学。医療経済学、交通安全経済学の分野で300以上の論文、書籍、報告書を発表している。スウェーデン歯科給付委員会およびスウェーデン医薬品価格・償還委員会の元メンバーとして、医薬品価格と償還の決定に10年の経験を持つ。

Pierre-Yves Geoffard　ピエール・イヴ・ジェオファール

Professor at Paris School of Economics and at Ecole des Hautes Etudes en Sciences Sociales, and a Senior Research Fellow at CNRS. He has been the director of the Paris School of Economics (2013-2019), and Previously director of the research center Paris jourdan Sciences Economiques, and director of the master and PhD programme Analyse et Politique Economiques. He holds a master degree in applied maths (University of Dauphine) and an other in Economics (EHESS), and a PhD in Applied Maths (University of Dauphine). He has been a visiting scholar at the Universities of Stanford, Chicago, Lausanne, and more recently Ca'Foscari in Venice. His main research projects focus on the analysis of health systems and their regulation. He has
published over 50 articles in academic journals (Econometrica, Biometrika, American Economic Review, Journal of Economic Theory, Journal of Health Economics, Health Economics, Health Affairs,...). He is the laureate of an ERC "Synergy" research grant (2019-2024) for a multidisciplinary research project on Gender and Socio-economic inequalities in Health.

パリ・スクール・オブ・エコノミクス教授、フランス国立社会科学高等研究院教授、フランス国立科学研究センター（CNRS）シニアリサーチフェロー。パリ・スクール・オブ・エコノミクス院長（2013-2019年）、パリ・ジュルダン・エコノミクス研究センター長、修士・博士課程 経済分析・政策プログラム長を歴任。応用数学修士（パリ・ドーフィン大学）、経済学修士（EHESS）、応用数学博士（パリ・ドーフィン大学）。スタンフォード大学、シカゴ大学、ローザンヌ大学、ヴェネツィア・カ・フォスカリ大学にて客員研究員。主な研究テーマは医療制度とその規制の分析。50以上の論文を学術誌（Econometrica、Biometrika、American Economic Review、Journal of Economic Theory、Journal of Health Economics、Health Economics、Health Affairs など）に発表。健康に関するジェンダーと社会経済的不平等についての複合研究プロジェクトにおいて、ERC「シナジー」研究助成金（2019-2024年）獲得。

J. Jaime Caro　J・ハイメ・カロ

MDCM, FRCPC, FACP, Professor in practice, LSE; Professor of Medicine, Epidemiology, Biostatistics (adj), McGill University; Honorary Visiting Associate Professor with the Saw Swee Hock School of Public Health, National University of Singapore; Chief Scientist, Evidera. For Germany's IQWiG, Dr. Caro proposed an innovative approach to health technology assessment, involving efficiency frontiers. His recent work involves leveraging hybrid growth/decay functions to forecast highly local COVID-19 trajectories; development of DICE 2.0, a unified approach to modeling that enables rapid, standardized and less error-prone forecasting models; a broader approach than QALYs to value health benefits, the BADIE. He led ISPOR-SMDM's task forces for Good Modeling Practices and Modeling Quality Assurance, and member ISPOR's Science and Research Committee.

MDCM、FRCPC、FACP、LSE担当教授、マギル大学生物統計学、疫学、医学部教授（兼任）、シンガポール国立大学公衆衛生学部名誉客員准教授、エビデラ社チーフサイエンティスト。ドイツのIQWiGにおいて、効率フロンティアを含む医療技術評価の革新的なアプローチを提案。最近の研究には、ハイブリッド成長・減衰関数を活用した局所性の高いCOVID-19軌道の予測、迅速かつ標準化され誤差の少ない予測モデルを可能にするモデリングへの統一アプローチであるDICE 2.0の開発、QALYよりも幅広いアプローチによるヘルスベネフィット評価、BADIEを含む。ISPOR-SMDMの「Good Modeling Practices」と「Modeling Quality Assurance」のタスクフォースを主導。ISPOR科学研究委員会メンバー。

Chee Jen Chang, PhD　張啟仁

Professor Chang is a distinguished professor at the Graduate Institute of Clinical Medical Science, the Department of Biomedical Science, and the Department of Artificial Intelligence at Chang Gung University, Taiwan. He earned his PhD from the University of Iowa, USA, and previously served as research faculty at the Albert Einstein College of Medicine in New York City. Prof. Chang, a biostatistics-trained methodologist, has key interests in the design and analysis of clinical trials and epidemiological big data. He is also an expert in Health Technology Assessment (HTA) research, specializing in methodologies for pharmaco-epidemiology, pharmaco-economics, cost-effectiveness analysis, and dynamic modeling,
particularly in the field of infectious diseases. Additionally, he serves on various government committees, including the new drug approval committee of the Taiwan Food and Drug Administration (TFDA) and the expert committee for new drug reimbursement in the National Health Insurance Administration (NHIA). He was president of the Taiwan Society for Pharmacoeconomics and Outcome Research (TASPOR) from 2012 to 2017 and also served as chairperson of ISPOR's Taiwan chapter. Moreover, he was chair-elect for the ISPOR Asia Consortium advisory board. Prof. Chang has published over 300 peer-reviewed articles in clinical and public health journals.

台湾 長庚大学 臨床医学研究院、生物医学部、人工知能学部 教授。米国アイオワ大学にて博士号を取得後、ニューヨークのアルバート・アインシュタイン医科大学にて研究員を務める。生物統計学を学んだメソドロジストであり、臨床試験と疫学ビッグデータのデザインと分析について研究。医療技術評価（HTA）研究の専門家でもあり、特に感染症分野における薬理疫学、医薬経済学、費用対効果分析、ダイナミック・モデリングの手法を中心に研究。また、台湾食品薬品監督管理局（TFDA）の新薬承認委員会や国民健康保険局（NHIA）の新薬償還専門委員会など、多くの政府委員会のメンバーを歴任。台湾医薬経済・アウトカム研究会（TASPOR）会長（2012〜2017年）、ISPOR台湾支部長、ISPORアジアコンソーシアム・アドバイザリーボード次期議長。臨床および公衆衛生ジャーナルに300以上の査読付き論文を発表。

Isao Kamae　鎌江 伊三夫

Graduated from Kyoto University, Faculty of Engineering and Graduate School of Engineering, Master of Engineering. Graduated from Kobe University, School of Medicine, MD. Harvard University, Doctor of Public Health. The founding President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Japan Chapter (2005-09). The first Japanese to serve on board members of relevant international societies (Board Director; ISPOR 2004-06, HTAi 2017-20), the first Asian to serve as President-Elect of ISPOR 2020-21 and President of ISPOR 2021-22, and a pioneer in health economics research in Japan.

京都大学工学部及び大学院卒業・工学修士。神戸大学医学部卒業・医師。
ハーバード大学公衆衛生学博士。国際医薬経済学・アウトカム研究学会(ISPOR)日本部会初代会長（2005-09年）。日本人として初めて関係国際学会の理事(ボードディレクター；ISPOR 2004-06年、 国際医療技術評価学会HTAi 2017-20）、またアジア人として初めてISPOR次期会長 2020-21年、ISPOR会長2021-22年を歴任する等、日本における医療経済研究の草分け。

Jeonghoon Ahn　アン・ジョンフン

Dr. Jeonghoon Ahn is a full professor at the Ewha Womans University (Seoul, Korea) and an adjunct fellow at the National Evidence-based healthcare Collaborating Agency (NECA), Seoul, Korea. He is an expert on health technology assessment (HTA) and health economics. Professor Ahn has graduated the Seoul National University Department of International Economics for undergraduate (1988-1992) and master program (1992-1994). He also received a PhD in Economics from the University of Southern California (USC) in 2000 and was an assistant professor of pharmaceutical economics and Policy at the USC (2002-2009). He worked 7 years in NECA (2009-2016) and served in various decision making and advisory committees of public agencies such as the Health Insurance Review and Assessment Services (HIRA) and the Korean Centers for Disease Control (KCDC). Dr. Ahn has served on international professional organizations such as Chair of the ISPOR Asia Consortium (2020-2022) and was the second president of ISPOR Korea Chapter (2012-2014). Dr. Ahn was elected as a board director of the Health Technology Assessment International (HTAi) (2014-2016) and a board director for the International Network of Agencies for Health Technology Assessment (INAHTA) for three times (2012-2016). He cofounded a regional Health Technology Assessment agency network, the HTAsiaLink and served as the inaugural secretary of the network (2011-2016).

梨花女子大学（韓国、ソウル）教授、National Evidence-based healthcare Collaborating Agency（NECA）（韓国、ソウル）非常勤研究員。医療技術評価（HTA）と医療経済学の専門家。ソウル国立大学国際経済学部卒業（1988〜1992年）、修士課程修了（1992〜1994年）。2000年、南カリフォルニア大学（USC）にて経済学博士号を取得。USC医薬経済・政策学助教授（2002〜2009年）。NECAに7年間勤務し（2009〜2016年）、Health Insurance Review and Assessment Services（HIRA）やKorean Centers for Disease Control（KCDC）など、公的機関の様々な意思決定や諮問委員会に携わる。ISPORアジアコンソーシアム議長（2020〜2022年）、ISPOR韓国支部第2代会長（2012〜2014年）など、国際的な専門組織で活躍。Health Technology Assessment International（HTAi）理事（2014〜2016年）。International Network of Agencies for Health Technology Assessment（INAHTA）理事を3期務める（2012〜2016年）。地域の医療技術評価機関ネットワーク「HTAsiaLink」を共同設立、初代事務局長（2011〜2016年）。